Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Olstein Capital Management L.P.

Olstein Capital Management L.P. trimmed its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 14.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 133,000 shares of the life sciences company's stock after selling 22,000 shares during the period. Olstein Capital Management L.P. owned approximately 0.17% of Integra LifeSciences worth $3,016,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP boosted its holdings in Integra LifeSciences by 0.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company's stock valued at $52,014,000 after acquiring an additional 12,766 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of Integra LifeSciences during the second quarter worth about $114,000. Thrivent Financial for Lutherans boosted its stake in shares of Integra LifeSciences by 233.9% in the second quarter. Thrivent Financial for Lutherans now owns 56,912 shares of the life sciences company's stock valued at $1,658,000 after purchasing an additional 39,868 shares during the period. AXA S.A. grew its holdings in shares of Integra LifeSciences by 409.1% in the second quarter. AXA S.A. now owns 96,689 shares of the life sciences company's stock valued at $2,818,000 after purchasing an additional 77,697 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in Integra LifeSciences by 90.9% during the 2nd quarter. AQR Capital Management LLC now owns 611,798 shares of the life sciences company's stock worth $17,436,000 after buying an additional 291,326 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares in the company, valued at $1,357,357.12. This represents a 2.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.10% of the company's stock.

Integra LifeSciences Stock Up 1.8 %

IART stock traded up $0.45 during trading on Friday, hitting $26.05. 551,282 shares of the company's stock were exchanged, compared to its average volume of 452,759. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -289.41, a PEG ratio of 0.83 and a beta of 1.16. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $45.42. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The business has a 50-day moving average price of $23.32 and a two-hundred day moving average price of $22.28.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same quarter in the previous year, the firm earned $0.76 EPS. The company's revenue was down .4% compared to the same quarter last year. As a group, equities research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on IART shares. Citigroup boosted their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research note on Tuesday, November 5th. Bank of America lowered their target price on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a research note on Monday, October 7th. BTIG Research raised Integra LifeSciences from a "sell" rating to a "neutral" rating in a research report on Monday, October 7th. Morgan Stanley assumed coverage on Integra LifeSciences in a research report on Monday, December 2nd. They set an "underweight" rating and a $20.00 price objective for the company. Finally, Truist Financial reduced their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, October 14th. Three analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $23.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.